Skip to main content
. 2023 May 18;14:1148019. doi: 10.3389/fpsyt.2023.1148019

Table 3.

Distribution of the demographic, clinical characteristics, and laboratory investigations of the study population with anxiety.

GAD7 Total Control COVID-19 n (%) n (%) χ 2 p
Demographic variable
Age group (years) 15–64 157 71 (45.2) 86 (54.8) 0.43 0.514 > 65 66 33 (50) 33 (50)
Gender Male 141 67 (47.5) 74 (52.5) 0.12 0.729 Female 82 37 (45.1) 45 (54.9)
Marital status Single 41 20 (48.8) 21 (51.2) 0.09 0.761 Married 182 84 (46.2) 98 (53.8)
Ethnic group Malay 138 66 (47.8) 72 (52.2) 1.31 0.727 Chinese 52 22 (42.3) 30 (57.7) Indian 18 10 (55.6) 8 (44.4) Others 15 6 (40) 9 (60)
Habits None 182 89 (48.9) 93 (51.1) 6.58 0.087 Smoking 34 15 (44.1) 19 (55.9) Alcohol 2 0 (0) 2 (100) Smoking and Alcohol 5 0 (0) 5 (100)
Education level None 6 3 (50) 3 (50) 2.75 0.432 Primary 58 31 (53.4) 27 (46.6) Secondary 133 56 (42.1) 77 (57.9) University 26 14 (53.8) 12 (46.2)
Employment Unemployed 138 76 (55.1) 62 (44.9) 10.35 0.001* Employed 85 28 (32.9) 57 (67.1)
Diagnosis of COVID-19 No 105 89 (84.8) 16 (15.2) 115.90 0.001* Yes 118 15 (12.7) 103 (87.3)
COVID-19 category Non-COVID 105 89 (84.8) 16 (15.2) 116.74 0.001* Category 1 8 2 (25) 6 (75) Category 2 16 2 (12.5) 14 (87.5) Category 3 26 2 (7.7) 24 (92.3) Category 4 57 8 (14) 49 (86) Category 5 11 1 (9.1) 10 (90.9)
Clinical characteristics
Respiratory symptoms (fever, runny nose, sore throat, shortness of breath, and cough) No 57 39 (68.4) 18 (31.6) 14.60 0.001* Yes 166 65 (39.2) 101 (60.8)
Fever No 99 55 (55.6) 44 (44.4) 5.69 0.017* Yes 124 49 (39.5) 75 (60.5)
Runny nose No 205 103 (50.2) 102 (49.8) 11.54 0.001* Yes 18 1 (5.6) 17 (94.4)
Sore throat No 193 101 (52.3) 92 (47.7) 17.03 0.001* Yes 30 3 (10) 27 (90)
Shortness of breath No 155 83 (53.5) 72 (46.5) 8.87 0.003* Yes 68 21 (30.9) 47 (69.1)
Cough No 134 85 (63.4) 49 (36.6) 38.06 0.001* Yes 89 19 (21.3) 70 (78.7)
Gastrointestinal symptoms (diarrhea, vomiting, abdominal pain, and poor oral intake) No 207 91 (44) 116 (56) 6.87 0.009* Yes 16 13 (81.3) 3 (18.8)
Diarrhea No 218 102 (46.8) 116 (53.2) 0.00 1.000 Yes 5 2 (40) 3 (60)
Vomiting No 220 101 (45.9) 119 (54.1) 1.65 0.200 Yes 3 3 (100) 0 (0)
Abdominal pain No 216 98 (45.4) 118 (54.6) 2.96 0.085 Yes 7 6 (85.7) 1 (14.3)
Poor oral intake No 219 100 (45.7) 119 (54.3) 2.73 0.098 Yes 4 4 (100) 0 (0)
Neurological symptoms (seizures, weakness, headache, and dizziness) No 181 94 (51.9) 87 (48.1) 10.84 0.001* Yes 42 10 (23.8) 32 (76.2)
Seizures No 220 102 (46.4) 118 (53.6) 0.01 0.906 Yes 3 2 (66.7) 1 (33.3)
Weakness No 217 102 (47) 115 (53) 0.06 0.805 Yes 6 2 (33.3) 4 (66.7)
Headache No 197 101 (51.3) 96 (48.7) 14.57 0.001* Yes 26 3 (11.5) 23 (88.5)
Dizziness No 212 100 (47.2) 112 (52.8) 0.49 0.484 Yes 11 4 (36.4) 7 (63.6)
Muscle and joint pain No 206 102 (49.5) 104 (50.5) 8.99 0.003* Yes 17 2 (11.8) 15 (88.2)
Laboratory investigations
Hemoglobin g/dL 12.0–15.0 99 43 (43.4) 56 (56.6) 0.73 0.392 Abnormal 124 61 (49.2) 63 (50.8)
White cell count × 109/L 4.0–10.0 124 53 (42.7) 71 (57.3) 1.70 0.192 Abnormal 99 51 (51.5) 48 (48.5)
Platelet × 109/L 150–410 167 78 (46.7) 89 (53.3) 0.00 0.971 Abnormal 56 26 (46.4) 30 (53.6)
Sodium mmol/L 136–145 115 61 (53) 54 (47) 3.92 0.048* Abnormal 108 43 (39.8) 65 (60.2)
Potassium mmol/L 3.5–5.1 176 87 (49.4) 89 (50.6) 2.62 0.105 Abnormal 47 17 (36.2) 30 (63.8)
Urea mmol/L 2.5–6.7 129 59 (45.7) 70 (54.3) 0.10 0.752 Abnormal 94 45 (47.9) 49 (52.1)
Creatinine μmol/L 50.4–98.1 124 53 (42.7) 71 (57.3) 1.70 0.192 Abnormal 99 51 (51.5) 48 (48.5)
Total protein g/L 64–83 170 75 (44.1) 95 (55.9) 1.82 0.177 Abnormal 53 29 (54.7) 24 (45.3)
Albumin g/L 34–48 106 47 (44.3) 59 (55.7) 0.43 0.513 Abnormal 117 57 (48.7) 60 (51.3)
Bilirubin μmol/L 3.4–20.5 183 88 (48.1) 95 (51.9) 0.86 0.353 Abnormal 40 16 (40) 24 (60)
Alanine transaminase IU/L 0–55 180 88 (48.9) 92 (51.1) 1.90 0.168 Abnormal 43 16 (37.2) 27 (62.8)
Alkaline phosphatase IU/L 40–150 191 90 (47.1) 101 (52.9) 0.13 0.724 Abnormal 32 14 (43.8) 18 (56.3)

*Significant p < 0.05; χ2 Chi-square test.